Following a limited submission
AWMSG advice |
|||
| Status: Recommended | |||
Dolutegravir (Tivicay®) is recommended as an option for use within NHS Wales in combination with other anti-retroviral medicinal products for the treatment of Human Immunodeficiency Virus (HIV) infected adults, adolescents and children above 6 years of age. This recommendation applies only in circumstances where the approved Wales Patient Access Scheme (WPAS) is utilised or where the list/contract price is equivalent or lower than the WPAS price. |
|||
|
|||
Medicine details |
|||
| Medicine name | dolutegravir (Tivicay®) | ||
| Formulation | 10 mg and 25 mg film-coated tablet | ||
| Reference number | 3373 | ||
| Indication | Treatment of Human Immunodeficiency Virus (HIV) infected adults, adolescents and children above 6 years of age, in combination with other anti-retroviral medicinal products |
||
| Company | ViiV Healthcare UK Ltd | ||
| BNF chapter | Infections | ||
| Submission type | Limited | ||
| Status | Recommended | ||
| Advice number | 2017 | ||
| NMG meeting date | 06/09/2017 | ||
| AWMSG meeting date | 11/10/2017 | ||
| Date of issue | 19/10/2017 | ||
| Date of last review | October 2020 | ||
| Commercial arrangement | WPAS | ||